Novo Integrated Sciences extends CEO resignation date to March 7, 2025; no successor named

Novo Integrated Sciences, Inc.

CEO Robert Mattacchione's resignation effective date extended to no later than March 7, 2025.
Mattacchione will remain as Chairman of the Board and Chairman of Novo Healthnet Limited subsidiary.
Resignation not due to any disagreement with company on operations, policies, or practices.
No replacement CEO has been announced; transition ongoing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Mattacchione

Chief Executive Officer

Novo Integrated Sciences, Inc.

Effective: 2025-03-07
Filed: February 25, 2025, 6:59 PM ET

on February 20, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to no later than March 7, 2025, in order to provide the Company the necessary time to complete an efficient transition of the Chief Executive Officer position.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Mattacchione resigned as Chief Executive Officer at Novo Integrated Sciences, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

on February 20, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to no later than March 7, 2025, in order to provide the Company the necessary time to complete an efficient transition of the Chief Executive Officer position.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-25-008216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.